The Thalassemia drugs in development market research report provides comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Thalassemia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Thalassemia and features dormant and discontinued products.

GlobalData tracks 75 drugs in development for Thalassemia by 64 companies/universities/institutes. The top development phase for Thalassemia is preclinical with 26 drugs in that stage. The Thalassemia pipeline has 68 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Thalassemia pipeline products market are: Vertex Pharmaceuticals, Novo Nordisk and San Rocco Therapeutics.

The key targets in the Thalassemia pipeline products market include Hemoglobin Subunit Beta (Beta Globin or Hemoglobin Beta Chain or HBB), Hemoglobin Subunit Gamma 1 (Gamma Globin or Gamma1 Globin or Hb F Agamma or Hemoglobin Gamma 1 Chain or Hemoglobin Gamma A Chain or HBG1), and Iron.

The key mechanisms of action in the Thalassemia pipeline product include Hemoglobin Subunit Beta (Beta Globin or Hemoglobin Beta Chain or HBB) Activator with ten drugs in Phase II. The Thalassemia pipeline products include six routes of administration with the top ROA being Intravenous and 11 key molecule types in the Thalassemia pipeline products market including Gene-Modified Cell Therapy, and Small Molecule.

Thalassemia overview

Thalassemia is a group of inherited blood disorders that affect the body’s ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite, and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.

For a complete picture of Thalassemia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.